GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SGN-1 overview
SGN-1 is under development for the treatment of liver cancer, head and neck cancer squamous cell carcinoma, non-hodgkin lymphoma, hodgkin lymphoma, skin cancer, sarcoma, pancreatic cancer, prostate cancer, pseudomyxoma peritoneum (pseudomyxoma peritonei, PMP), squamous non-small cell carcinoma, cervical carcinoma, breast cancer, triple negative breast cancer, melanoma, head and neck cancer, ovarian cancer, small-cell lung cancer, bladder cancer, nasopharyngeal cancer and hepatocellular carcinoma. The drug candidate is administered by intratumoral and intravenous routes. It acts by targeting amino acid metabolism.
It was also under development for the treatment of osteosarcoma and penile cancer.
For a complete picture of SGN-1’s drug-specific PTSR and LoA scores, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.